James Aloysius Brady

CIK: 0001916987

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (22.2%)

Position reduction

Option Exercises (M)2 (22.2%)

Derivative conversions

Awards (A)3 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)2 (22.2%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

XERS

Xeris Biopharma Holdings, Inc.

Director

VRNA

Verona Pharma plc

Director

Discretionary Trading P&L

Holdings

Transaction History (9 total)

XERS
Xeris Biopharma Holdings, Inc.
Jun 4, 2026
Award(A)
Direct
24.2K shares-
XERS
Xeris Biopharma Holdings, Inc.
Mar 30, 2026
Sale(S)
Direct
10.8K shares at avg. $5.54$60K
VRNA
Verona Pharma plc
Oct 7, 2025
Exercise(M)
Direct
72K shares-
VRNA
Verona Pharma plc
Oct 7, 2025
Disposition(D)
Direct
72K shares-
VRNA
Verona Pharma plc
Oct 7, 2025
Disposition(D)
Direct
23.2K shares-
VRNA
Verona Pharma plc
Aug 1, 2025
Sale(S)
Direct
824 shares at avg. $13.14$11K
VRNA
Verona Pharma plc
Aug 1, 2025
Exercise(M)
Direct
24K shares-
VRNA
Verona Pharma plc
Apr 25, 2025
Award(A)
Restricted Share Units
Direct
96K shares-
XERS
Xeris Biopharma Holdings, Inc.
Mar 28, 2025
Award(A)
Direct
100K shares-

		Type	Shares	Price		Ownership
Jun 4, 2026	XERS Xeris Biopharma Holdings, Inc.	Award(A)	24,193	-	$0	Direct
Mar 30, 2026	XERS Xeris Biopharma Holdings, Inc.	Sale(S)	10,834	$5.54	$60,036	Direct
Oct 7, 2025	VRNA Verona Pharma plc	Exercise(M)	72,000	-	-	Direct
Oct 7, 2025	VRNA Verona Pharma plc	Disposition(D)	72,000	-	-	Direct
Oct 7, 2025	VRNA Verona Pharma plc	Disposition(D)	23,176	-	-	Direct
Aug 1, 2025	VRNA Verona Pharma plc	Sale(S)	824	$13.14	$10,830	Direct
Aug 1, 2025	VRNA Verona Pharma plc	Exercise(M)	24,000	-	-	Direct
Apr 25, 2025	VRNA Verona Pharma plc	Award(A) Restricted Share Units	96,000	-	-	Direct
Mar 28, 2025	XERS Xeris Biopharma Holdings, Inc.	Award(A)	100,000	-	-	Direct

1-9 of 9 transactions

About Brady James Aloysius

Brady James Aloysius (SEC CIK 0001916987) files insider reports with the SEC as Director of Xeris Biopharma Holdings, Inc. (XERS) and Director of Verona Pharma plc (VRNA).

Signal8 holds 7 ownership filings by Brady James Aloysius (1 Form 3, 6 Form 4), filed between Mar 28, 2025 and Jun 5, 2026. Those filings report 9 transactions, from Mar 28, 2025 to Jun 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Brady James Aloysius's filings is in CHICAGO, IL.

Recent filings by Brady James Aloysius

Jun 4, 2026: Grant or award of XERS shares (Form 4, code A).
Mar 30, 2026: Open-market sale of XERS shares (Form 4, code S).
Oct 7, 2025: Option exercise of VRNA shares (Form 4, code M).
Oct 7, 2025: Disposition to issuer transactions of VRNA shares (2 lines, Form 4, code D).
Aug 1, 2025: Open-market sale of VRNA shares (Form 4, code S).

Other insiders filing for Xeris Biopharma Holdings, Inc. (XERS)

How to read Form 4 transaction codes